Prognostic value of breast cancer aromatase.
The estrogen receptor, progesterone receptor, and intratumoral aromatase content of 127 breast carcinomas were determined. Patients whose tumor contained either estrogen or progesterone receptors had a longer disease-free interval, but no difference in survival was observed. Measurable aromatase activity was detected in 78 of 113 (69%) tumors. There was no relationship between aromatase activity and disease-free interval or survival.